Future studies assessing the roles of nasopharyngeal ACE2 and TMPRSS2 in SARS-CoV-2 infection and COVID-19 disease severity should include a larger number of random family clusters that include symptomatic patients, as well as those with different levels of severity. The gene discussed is ACE2; the disease is COVID-19.